US FDA Title 21 CFR Part 4 Pocket Guide
- cGMP for Combination Products
This regulation pertains to products comprised of any combination of a drug and a device; a device
and a biological product; a biological product and a drug; or a drug, a device, and a biological product.
The FDA intended for the rule to help ensure that CGMP requirements that apply to single-entity and co-packaged combination products are clear and consistent, regardless of which Agency component has lead jurisdiction for the combination product, or which type of application is submitted for marketing authorization. The proposed rule was also intended to streamline demonstrating compliance with CGMP requirements for these types of combination products and to help ensure appropriate implementation of these requirements while avoiding
unnecessary redundancy in CGMP operating systems for these products.